Design and synthesis of fluorinated iron chelators for metabolic study and brain uptake

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 2185-2195

  Ma, Yongmin ^a   Roy, Sourav ^a   Kong, Xiaole ^a   Chen, Yulin ^a   Liu, Dingyong ^a   Hider, Robert C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 4 PYRIDONE; BUFFER; DEFERIPRONE; FLUORINE; HYDROXYL GROUP; IRON CHELATING AGENT; IRON COMPLEX; LIGAND; OCTANOL; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CORRELATION COEFFICIENT; GLUCURONIDATION; LIPOPHILICITY; OXIDATION; PKA; SYNTHESIS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; COORDINATION COMPLEXES; CYTOCHROME P-450 ENZYME SYSTEM; FERROUS COMPOUNDS; FLUORINE; GLUCURONIDES; GUINEA PIGS; HYDROGEN-ION CONCENTRATION; IRON CHELATING AGENTS; MICROSOMES, LIVER; OXIDATION-REDUCTION; PERMEABILITY; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863247972     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201475u     Document Type: Article

References (25)

1. Bohm, H. J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Muller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry ChemBioChem 2004, 5, 637-643
2. Dolbier, W. R. Fluorine chemistry at the millennium J. Fluorine Chem. 2005, 126, 157-163
3. Hagmann, W. K. The many roles for fluorine in medicinal chemistry J. Med. Chem. 2008, 51, 4359-4369
4. Muller, K. Unveiling the mystery and beauty of organic fluorine ChemBioChem 2004, 5, 559-562
5. MDL Drug Data Report (MDDR); MDL Information Services, Inc., Elsevier MDL: San Ramon, CA, 2007; Vol. 2007.2.
6. Mandel, S.; Grunblatt, E.; Riederer, P.; Gerlach, M.; Levites, Y.; Youdim, M. B. Neuroprotective strategies in Parkinson's disease: an update on progress CNS Drugs 2003, 17, 729-762
7. Boddaert, N.; Le Quan Sang, K. H.; Rotig, A.; Leroy-Willig, A.; Gallet, S.; Brunelle, F.; Sidi, D.; Thalabard, J. C.; Munnich, A.; Cabantchik, Z. I. Selective iron chelation in Friedreich ataxia: biologic and clinical implications Blood 2007, 110, 401-408
8. Roy, S.; Preston, J. E.; Hider, R. C.; Ma, Y. M. Glucosylated deferiprone and its brain uptake: implications for developing glucosylated hydroxypyridinone analogues intended to cross the blood-brain barrier J. Med. Chem. 2010, 53, 5886-5889
9. Singh, S.; Epemolu, R. O.; Dobbin, P. S.; Tilbrook, G. S.; Ellis, B. L.; Damani, L. A.; Hider, R. C. Urinary Metabolic Profiles in Human and Rat of 1,2-Dimethyl-Substituted and 1,2-Diethyl-Substituted 3-Hydroxypyridin-4-ones Drug Metab. Dispos. 1992, 20, 256-261
10. Balfour, J. A. B.; Foster, R. H. Deferiprone-a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases Drugs 1999, 58, 553-578
11. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Luchetta, G.; Creary, E. A.; Peter, H. H. A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-hydroxypyrid-4-one, 1,2-Diethyl-3-hydroxypyrid-4-one, and Deferoxamine Blood 1992, 79, 1882-1890
12. Porter, J. B.; Abeysinghe, R. D.; Hoyes, K. P.; Barra, C.; Huehns, E. R.; Brooks, P. N.; Blackwell, M. P.; Araneta, M.; Brittenham, G.; Singh, S.; Dobbin, P.; Hider, R. C. Contrasting Interspecies Efficacy and Toxicology of 1,2-Diethyl-3-hydroxypyridin-4-one, Cp94, Relates to Differing Metabolism of the Iron-Chelating Site Br. J. Haematol. 1993, 85, 159-168
13. Porter, J. B.; Morgan, J.; Hoyes, K. P.; Burke, L. C.; Huehns, E. R.; Hider, R. C. Relative Oral Efficacy and Acute Toxicity of Hydroxypyridin-4-One Iron Chelators in Mice Blood 1990, 76, 2389-2396
14. Lu, S. L.; Gosriwatana, I.; Liu, D. Y.; Liu, Z. D.; Mallet, A. I.; Hider, R. C. Biliary and urinary metabolic profiles of 1,2-diethyl-3-hydroxypyridin-4- one (CP94) in the rat Drug Metab. Dispos. 2000, 28, 873-879
15. Liu, Z. D.; Kayyali, R.; Hider, R. C.; Porter, J. B.; Theobald, A. E. Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4- ones: structure-activity investigation of metalloenzyme inhibition by iron chelators J. Med. Chem. 2002, 45, 631-639
16. Piyamongkol, S.; Liu, Z. D.; Hider, R. C. Novel synthetic approach to 2-(1′-hydroxyalkyl)- and 2-amido-3-hydroxypyridin-4-ones Tetrahedron 2001, 57, 3479-3486
17. Bobbio, C.; Schlosser, M. Selective functionalization of 2-fluoropyridine, 2,3-difluoropyridine, and 2,5-difluoropyridine at each vacant position J. Org. Chem. 2005, 70, 3039-3045
18. Estel, L.; Marsais, F.; Queguiner, G. Metalation Srn1 Coupling in Heterocyclic Synthesis-A Convenient Methodology for Ring Functionalization J. Org. Chem. 1988, 53, 2740-2744
19. 2)(2)OLi (BuLi-LiDMAE) J. Chem. Soc., Perkin Trans. 1 1997, 3071-3080
20. Ma, Y. M.; Hider, R. C. Design and synthesis of fluorine-substituted 3-hydroxypyridin-4-ones Tetrahedron Lett. 2010, 51, 5230-5233
21. Dobbin, P. S.; Hider, R. C.; Hall, A. D.; Taylor, P. D.; Sarpong, P.; Porter, J. B.; Xiao, G.; van der Helm, D. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1 H)-pyridinones: orally active iron chelators with clinical potential J. Med. Chem. 1993, 36, 2448-2458
22. Garribba, E.; Rangel, M.; Leite, A.; Amorim, M. J.; Micera, G.; Lodyga-Chruscinska, E. Spectroscopic and potentiometric characterization of oxovanadium(IV) complexes formed by 3-hydroxy-4-pyridinones. Rationalization of the influence of basicity and electronic structure of the ligand on the properties of (VO)-O-IV species in aqueous solution Inorg. Chem. 2006, 45, 8086-8097
23. a values. Dalton Trans. 2012, DOI: 10.1039/C2DT12396G, in press.
24. Brown, H. C.; Mcdaniel, D. H. Steric Effects in Displacement Reactions 0.7. The Base Strengths and Ultraviolet Absorption Spectra of the 2-Monohalopyridines and 3-Monohalopyridines J. Am. Chem. Soc. 1955, 77, 3752-3755
25. Rai, B. L.; Dekhordi, L. S.; Khodr, H.; Jin, Y.; Liu, Z.; Hider, R. C. Synthesis, physicochemical properties, and evaluation of N -substituted-2-alkyl- 3-hydroxy-4(1 H)-pyridinones J. Med. Chem. 1998, 41, 3347-3359